Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 9,974 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TARGET Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Craving Network Neurofeedback

NCT06426693
View directory record Official record
Conditions
Overweight or Obesity
Interventions
Experimental feedback, Control feedback
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 3:15 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
SAR446523
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention

NCT01752504
View directory record Official record
Conditions
HIV Infection
Interventions
Community Mobilization
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

NCT03653247
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plerixafor, Busulfan, BIVV003
Biological · Drug · Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Oakland, California • Sacramento, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 30, 2026, 3:15 AM EDT
Recruiting Early Phase 1 Interventional

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828
View directory record Official record
Conditions
Advanced Basal Cell Carcinoma
Interventions
Vismodegib 150 MG Oral Capsule
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Not yet recruiting Not applicable Interventional

Sleep MAPP in the Polytrauma/TBI System of Care

NCT07886398
View directory record Official record
Conditions
Insomnia Disorder, Mild Traumatic Brain Injury
Interventions
Sleep MAPP Care Pathway
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional

MGH Trauma-related Nightmares SDI Study

NCT05195684
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
imaginal probe
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors

NCT03279055
View directory record Official record
Conditions
Insomnia
Interventions
SHUTi
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
14 Years to 25 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

Fluphenazine Hydrochloride for Psoriasis

NCT00929578
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 30, 2026, 3:15 AM EDT
Not listed Not applicable Interventional

Online Treatment Recovery Assistance for Concussion in Kids

NCT05065099
View directory record Official record
Conditions
Concussion, MTBI - Mild Traumatic Brain Injury
Interventions
Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 17 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 30, 2026, 3:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

NCT04061421
View directory record Official record
Conditions
MDS/MPN
Interventions
ASTX727, Itacitinib, Ruxolitinib
Drug
Lead sponsor
Michael Savona
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

NCT05630716
View directory record Official record
Conditions
Sepsis, Hypotension, Septic Shock
Interventions
NICOM
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 30, 2026, 3:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

NCT03779334
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Day to 6 Weeks
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes

NCT00344344
View directory record Official record
Conditions
Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 3:15 AM EDT
Not listed Early Phase 1 Interventional

Responsive Neurostimulation for Post-Traumatic Stress Disorder

NCT04152993
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
NeuroPace® RNS® System
Device
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
25 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

NCT01572948
View directory record Official record
Conditions
COPD
Interventions
roflumilast, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 30, 2026, 3:15 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

NCT05488444
View directory record Official record
Conditions
Breast Cancer
Interventions
Navigator Phone Calls, Exit Interview
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 30, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain

NCT02439437
View directory record Official record
Conditions
Breast Cancer
Interventions
Psychosocial Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 30, 2026, 3:15 AM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Acapatamab, Enzalutamide, Abiraterone, AMG 404
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 3:15 AM EDT
Not yet recruiting Phase 2 Interventional

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

NCT07146230
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Monalizumab, Oleclumab, Radiotherapy
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 30, 2026, 3:15 AM EDT